Dentsply SironaXRAY
Recorded

Dentsply Sirona 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration32 minParticipants9

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good day, and thank you for standing by. Welcome to the Q3 2026 DENTSPLY SIRONA earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference call is being recorded. I would now like to hand the conference over to the first speaker today, Suzanne Hatcher, Investor Relations.

Suzanne HatcherInvestor Relations

Please go ahead. Thank you, Stephanie.

Suzanne HatcherInvestor Relations

Welcome to the DENTSPLY SIRONA third quarter 2026 earnings call. Joining me for today's call are Dan Scavilla, President and Chief Executive Officer, and John Fortson, Executive Vice President and Chief Financial Officer. I'd like to remind you that an earnings press release and slide presentation related to the call are available on the Investors section of our website at www.dentsplysirona.com. Before we begin, please take a moment to read the forward-looking statements in our earnings press release. During today's call, we may make certain forward-looking statements that reflect our current views about future performance and financial results. We base these statements and certain assumptions and expectations on future events that are subject to risks and uncertainties.

Suzanne HatcherInvestor Relations

Our most recently filed Form 10-K and any updated information in subsequent Form 10-Q or other SEC filings list some of the most important risk factors that could cause actual results to differ from our predictions. On today's call, our remarks will be based on non-GAAP financial results. We believe that non-GAAP financial measures offer investors valuable additional insights into our business's financial performance, enable the comparison of financial results between periods where certain items may vary independently of business performance, and enhance transparency regarding key metrics utilized by management in operating our business. Please refer to our press release for the reconciliation between GAAP and non-GAAP results. Comparisons provided are to the prior year quarter unless otherwise noted. A webcast replay of today's call will be available on the Investors section of the company's website following this call.

Suzanne HatcherInvestor Relations

With that, I will now turn the call over to Dan.

Dan ScavillaPresident and CEO

Thank you, Suzanne, and good afternoon, everyone. We continue to advance our Return-to-Growth Action Plan in the third quarter. We expanded customer access, strengthened our commercial organization, and increased investment in clinical education and innovation. Wellspect Healthcare delivered record sales, and we are seeing green shoots in parts of our U.S. dental business. We are making progress, but our results are not yet where they need to be. Our priority is now turning early gains into broader sustained improvement through stronger execution. We now expect full-year net sales of approximately $3.5 billion versus the range of $3.5 billion-$3.6 billion previously, and adjusted EPS of $1.20-$1.30 from $1.40 to $1.50, excluding the $0.17 one-time gain from tariff refunds. Additional cost actions have not fully offset business pressures as we continue to invest in our sales force, clinical education, and innovation.

Dan ScavillaPresident and CEO

As stated before, these investments will continue because they are essential to returning to sustainable growth. Before I turn the call over, John joined us in July and has now completed his first full quarter with DENTSPLY SIRONA. He brings a practical approach to improving performance and has already built close, trusted relationships with our teams to strengthen financial visibility and challenge cost. He is an excellent partner, and I am confident he will continue to make significant contribution to DENTSPLY SIRONA.

John FortsonEVP and CFO

John, over to you. Thanks, Dan, and good afternoon, everyone.

John FortsonEVP and CFO

Since joining DENTSPLY SIRONA, I have met with our teams, distributors, and partners to better understand our businesses, financial performance, and return to growth opportunities. These discussions have reinforced my confidence in our brands, customer relationships, and innovation capabilities. We have tangible progress to build on. As Dan shared, Wellspect delivered double-digit record revenue growth this quarter, supported by new products, and we saw positive momentum in the U.S. dental business. We remain diligent on costs in a dynamic environment while investing in our Return-to-Growth Action Plan. We are also strengthening our financial systems and access to detailed data to support better decisions. My priorities are to translate these capabilities into more consistent execution, disciplined investment, and stronger cash generation. Let's move to Q3 results. Third quarter revenue was $836 million, down 7.6% as reported and 7% in constant currency.

John FortsonEVP and CFO

The decline reflected continued pressure across our dental businesses, including the absence of Byte revenue and planned dealer inventory reductions. Excluding Byte, approximately $10 million of planned dealer inventory reductions and other discrete one-time events, revenue declined 3.8% in constant currency. Turning to profitability, adjusted gross margin improved 190 basis points year-over-year, while adjusted gross profit declined approximately $20 million. These results included a $39 million benefit from a change in accounting estimate in preparation for the implementation of a new financial consolidation system. More detailed data enabled us to refine our estimate of profit included in inventory transfer between our businesses. This increased third quarter gross profit and pre-tax income by approximately $39 million. The benefit reflects a multi-year period rather than third quarter operating performance, and we do not expect a similar benefit in future periods.

John FortsonEVP and CFO

We will continue to refine and improve our ability to analyze and forecast our business. Lower dental volumes and higher distribution costs weighed on gross profit, partially offset by cost management initiatives and favorable manufacturing absorption. Adjusted operating expenses increased $3 million year over year as we continued to invest in sales, clinical education, and R&D to support our Return-to-Growth Action Plan, partially offset by cost management initiatives. Together, these factors resulted in a 110 basis point decline in adjusted EBITDA margin. Adjusted EPS were $0.29 in the third quarter, down $0.13 from the prior year quarter. Turning to cash flow, operating cash flow was $32 million compared with $79 million in the prior year quarter. The decrease was primarily driven by unfavorable working capital. In the third quarter, we opportunistically repurchased 1.2 million shares.

John FortsonEVP and CFO

This is the second consecutive quarter where we have executed share repurchases, returning $25 million to shareholders through repurchases year to date. We finished the quarter with cash and cash equivalents of $195 million, and our third quarter net debt to EBITDA ratio was 3.4. We continue to prioritize debt reduction as a core tenet of our capital allocation strategy. Let's now turn to third quarter segment performance. CTS sales were $230 million, down 11% as reported. Growth in instruments in EMEA and the Americas and Japan CAD/CAM partially offset broader equipment headwinds. Equipment and instruments revenue was $137 million, down high single digits as reported. Instruments grew low single digits, supported by U.S. momentum through our ADAC partnership and 4% growth in Intego handpieces in EMEA, partially offsetting lower global imaging volumes.

John FortsonEVP and CFO

CAD/CAM revenue was $93 million as reported, primarily reflecting lower Americas volumes from the planned strategic inventory shift with distributors. APAC partially offset the decline, led by strong intraoral scanner and mill performance in Japan. In EMEA, pricing pressure from lower-cost entrants and softer capital demand weighed on results as uncertainty surrounding the Middle East conflict led some providers to defer investments. Turning to EDS, which includes endodontic, restorative, and preventive products, sales declined 4% as reported to $343 million, primarily driven by lower endodontic volumes and lower pricing in EMEA. Higher Americas volumes, led by strong file growth and restorative blocks, partially offset the decline. U.S. Endo returned to growth for the first time since Q2 2025, while Preventive grew double digits in EMEA and APAC. OAS revenue was $171 million, down 17% as reported, including a 6% Byte year-over-year negative impact.

John FortsonEVP and CFO

IPS revenue declined to $132 million as lower global premium implant volumes were partially offset by double-digit U.S. growth in MIS, our value implant brand. In ortho, SureSmile revenue declined to $39 million, primarily attributable to the absence of Byte sales and lower U.S. volumes. EMEA growth of 8% partially offset the decline, marking the region's sixth quarter of mid-single digit or better growth in seven quarters year over year. Wellspect Healthcare revenue increased 10% to $92 million as reported, driven by higher volumes and strong new product sales, particularly Surity in the U.S. market. Wellspect has delivered consistent growth throughout 2026 as investments begun in 2025 drive new products, broader market reach, and sustained commercial momentum. Now let's discuss our 2026 outlook.

John FortsonEVP and CFO

As Dan shared at the start of the call, we now expect full-year net sales of approximately $3.5 billion, compared with our previous range of $3.5 billion-$3.6 billion, and adjusted EPS of $1.20-$1.30 from $1.40-$1.50, excluding the $0.17 one-time gain from tariff refunds. This revision reflects a prudent response while sustaining investment in sales, clinical education, and innovation, areas historically underfunded and that are essential to our future growth. U.S. performance met expectations with momentum building, while Wellspect delivered record quarterly sales. EMEA distributor inventory reductions, the Middle East conflict, and higher freight costs continued to pressure results. Relative to prior EPS guidance, EMEA underperformance and the Middle East conflict accounted for roughly three-fourths of the reduction, with an unfavorable tax rate and strategic investments representing the balance. The profit included an inventory benefit, and cost management initiatives provided partial offsets.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day